Sylvain Chemtob is a neonatologist and pharmacologist, and professor of Pediatrics, with joint appointments in Pharmacology and Ophthalmology at Université de Montréal. His research is focused on reactive oxygen species and lipid mediators in ischemic neuropathies (eg. retinopathy of prematurity, stroke) with emphasis on the developing subject. He pioneered the concept of functional nuclear G protein-coupled receptors. He has also developed two powerful rationale drug design platform technologies enabling the rapid generation of antagonists to cell surface proteins (receptors, channels, etc); this has resulted in 2 spin-off companies (Pharma-G, Allostera Pharmaceuticals), and licensing of compounds. He is author of more than 160 articles reported in major journals, as well as inventor of 7 patents.